Gliptin and GLP‐1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide‐induced endotoxemia

@article{Steven2015GliptinAG,
  title={Gliptin and GLP‐1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide‐induced endotoxemia},
  author={Sebastian Steven and Michael Hausding and Swenja Kr{\"o}ller-Sch{\"o}n and Michael Mader and Yuliya Mikhed and Paul Stamm and Elena Zinssius and Amanda Pfeffer and Philipp Welschof and Saule Agdauletova and Stephan Sudowe and Huige Li and Matthias Oelze and Eberhard Schulz and Thomas Klein and Thomas F. M{\"u}nzel and Andreas Daiber},
  journal={Basic Research in Cardiology},
  year={2015},
  volume={110},
  pages={1-14}
}
Dipeptidyl peptidase (DPP)-4 inhibitors are used to treat hyperglycemia by increasing the incretin glucagon-like peptide-1 (GLP-1). Previous studies showed anti-inflammatory and antiatherosclerotic effects of DPP-4 inhibitors. Here, we compared the effects of linagliptin versus sitagliptin and liraglutide on survival and vascular function in animal models of endotoxic shock by prophylactic therapy and treatment after lipopolysaccharide (LPS) injection. Gliptins were administered either orally… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

potential implications in cardiovascular disease

  • J Zhong, X Rao, control Rajagopalan S An emerging role of dipeptidyl pepti glucose
  • Atherosclerosis 226: 305–314. doi:10.1016/j…
  • 2015
Highly Influential
18 Excerpts

Similar Papers

Loading similar papers…